NSCLC: Molecular Testing in the Metastatic Setting
The discussion on biomarker testing practices for patients with non–small cell lung cancer turns its focus to the metastatic setting.
Biomarker Testing in Non–Small Cell Lung Cancer
A panel of medical oncologists introduce themselves and provide clinical insights on biomarker testing practices for patients with non–small cell lung cancer.
HER3-DXd and the Evolving Treatment Paradigm in EGFR-mutated NSCLC
The panel discusses how HER3-directed therapy with patritumab deruxtecan may fit into the evolving treatment paradigm for EGFR-positive lung cancer as more data emerges.
HER3-DXd Safety and Strategies to Optimize Patient Outcomes
Dr. Yu and Dr. Patel examine the safety profile of patritumab deruxtecan, including adverse event monitoring and management approaches to optimize patient outcomes.
HERTHENA-Lung01: Patritumab Deruxtecan (HER3-DXd) in Previously Treated Metastatic EGFR-Mutated NSCLC: Efficacy Data and Sequencing Considerations
The expert panel analyze results from the HERTHENA-Lung01 trial, discuss efficacy outcomes with patritumab deruxtecan in pretreated EGFR-mutant metastatic NSCLC.
Targeting HER3 to Overcome Resistance in EGFR-mutated NSCLC: Patritumab Deruxtecan
Dr. Patel and Dr. Yu review the rationale for targeting HER3 as a novel approach to address acquired resistance in EGFR-mutant NSCLC.
Unmet Needs and Emergent Studies in EGFR Mutated NSCLC
Expert medical oncologists examine remaining unmet needs in managing EGFR-positive lung cancer, including overcoming resistance to initial EGFR-directed therapy. The panel discusses ongoing trials targeting these needs.
The Evolving Treatment Landscape in EGFR Mutated NSCLC and the Role of Comprehensive Genetic Testing in Guiding Treatment
Dr. Yu and Dr. Patel provide an overview of current standards and recent advances in the treatment landscape for EGFR-mutated NSCLC, emphasizing the critical role of comprehensive genomic profiling in guiding optimal therapy selection and sequencing.
NSCLC: Moving Second-Line Therapies to Frontline Setting
Helena A. Yu, MD, and Joshua K. Sabari, MD, look to the future of frontline treatment in EGFR exon 20–mutated non–small cell lung cancer.
Clinical Implications of Real-World Amivantamab Data in NSCLC
Lung cancer experts discuss how these real-world data comparing amivantamab with alternative therapies may impact their clinical practice.
Overview of Real-World Comparative Data for Amivantamab in NSCLC
Joshua K. Sabari, MD, and Helena A. Yu, MD, discuss real-world data comparing amivantamab with other therapies in EGFR exon 20–mutated non–small cell lung cancer.
Real-World Analysis of Amivantamab vs Other Therapies in Exon 20–Mutated NSCLC: Methods
A comprehensive overview of the methods utilized in a real-world analysis of amivantamab vs other therapies in patients with EGFR exon 20–mutated NSCLC.
CHRYSALIS: Amivantamab in Patients with Advanced NSCLC
Expert oncologists review the CHRYSALIS trial, which resulted in the approval of amivantamab in the second line for patients with locally advanced or metastatic NSCLC with exon 20 mutations.
Treatment Options for Patients with EGFR Exon 20–Mutated NSCLC
Experts on non–small cell lung cancer discuss treatment options for patients with EGFR exon 20 mutations in the first line and beyond.
Overview of EGFR Exon 20 Mutations
Joshua K. Sabari, MD, and Helena A. Yu, MD, experts on non–small cell lung cancer, give an overview of EGFR exon 20 insertion mutations.
